|
WO2021067598A1
|
|
Methods for improved therapeutic use of recombinant aav
|
|
WO2020243002A1
|
|
Compositions and methods for treatment of hemochromatosis
|
|
US2020325455A1
|
|
Engineered producer cell lines and methods of making and using the same
|
|
WO2020142653A1
|
|
Gene therapy constructs for treating wilson disease
|
|
WO2020132115A1
|
|
Methods and compositions for treating glycogen storage diseases
|
|
WO2020072451A1
|
|
Gene therapy for treating propionic acidemia
|
|
KR20200105833A
|
|
Creatine prodrugs, compositions and methods of use
|
|
CN110719954A
|
|
Therapeutic agent for glycogen storage disease type III
|
|
US2020124505A1
|
|
Scalable method for producing transfection reagents
|
|
US2020048641A1
|
|
Methods for enhancing yield of recombinant adeno-associated virus
|
|
EP3601581A1
|
|
Cell culture methods involving hdac inhibitors or rep proteins
|
|
EP3526321A1
|
|
Use of tonicifying agents to enhance recombinant adeno-associated virus yield
|
|
EP3484493A1
|
|
Use of glucocorticoid analogs to enhance recombinant adeno-associated virus yield
|
|
AU2017241777A1
|
|
Methods of heat inactivation of adenovirus
|
|
MX2018005352A
|
|
Methods and compositions for the treatment of amyloidosis.
|
|
WO2017048817A1
|
|
Crystal forms of sialic acid or salt or solvate thereof
|
|
EP3280406A1
|
|
Compositions and methods for treatment of movement disorders
|
|
PE20161417A1
|
|
COMPOSITIONS OF SIALYLATED GLYCOPROTEINS AND USE OF THEM
|
|
KR20160084407A
|
|
Solid compositions of triglycerides and uses thereof
|
|
WO2015069699A1
|
|
Creatine analogs and the use thereof
|
